Fig. 5From: Improve dosimetric outcome in stage III non-small-cell lung cancer treatment using spot-scanning proton arc (SPArc) therapya The distribution of MUs and energies for all the beamlets used between SPArc and RO-IMPT for patient 6. b The integral dose, MU, and the calculated total energy depositions (CTED) ratios for the fourteen patients between RO-IMPT and SPArc plansBack to article page